- Home
- ANNX vs DBL Comparison
ANNX vs DBL Comparison
Compare ANNX & DBL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANNX
- DBL
- Stock Information
- Founded
- ANNX 2011
- DBL 2011
- Country
- ANNX United States
- DBL United States
- Employees
- ANNX N/A
- DBL N/A
- Industry
- ANNX Biotechnology: Pharmaceutical Preparations
- DBL
- Sector
- ANNX Health Care
- DBL
- Exchange
- ANNX Nasdaq
- DBL Nasdaq
- Market Cap
- ANNX 263.3M
- DBL 296.0M
- IPO Year
- ANNX 2020
- DBL N/A
- Fundamental
- Price
- ANNX $2.50
- DBL $15.28
- Analyst Decision
- ANNX Strong Buy
- DBL
- Analyst Count
- ANNX 4
- DBL 0
- Target Price
- ANNX $12.50
- DBL N/A
- AVG Volume (30 Days)
- ANNX 1.8M
- DBL 61.0K
- Earning Date
- ANNX 08-11-2025
- DBL 01-01-0001
- Dividend Yield
- ANNX N/A
- DBL 8.67%
- EPS Growth
- ANNX N/A
- DBL N/A
- EPS
- ANNX N/A
- DBL N/A
- Revenue
- ANNX N/A
- DBL N/A
- Revenue This Year
- ANNX N/A
- DBL N/A
- Revenue Next Year
- ANNX N/A
- DBL N/A
- P/E Ratio
- ANNX N/A
- DBL N/A
- Revenue Growth
- ANNX N/A
- DBL N/A
- 52 Week Low
- ANNX $1.29
- DBL $13.75
- 52 Week High
- ANNX $7.85
- DBL $15.70
- Technical
- Relative Strength Index (RSI)
- ANNX 53.37
- DBL 42.67
- Support Level
- ANNX $2.50
- DBL $15.24
- Resistance Level
- ANNX $2.97
- DBL $15.37
- Average True Range (ATR)
- ANNX 0.27
- DBL 0.09
- MACD
- ANNX -0.02
- DBL -0.01
- Stochastic Oscillator
- ANNX 58.73
- DBL 24.97
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
About DBL DoubleLine Opportunistic Credit Fund of Beneficial Interest
Doubleline Opportunistic Credit Fund operates as a closed-end management investment company. Its investment objective is to seek a high total investment return by providing a high level of current income and the potential for capital appreciation. The Fund invests in debt securities, residential and commercial mortgage-backed securities, asset-backed securities, U.S. Government securities, corporate debt, international sovereign debt, and short-term investments.